about
Time course and predictors for cancer-related fatigue in a series of oropharyngeal cancer patients treated with chemoradiation therapyAnnotating STEAP1 regulation in prostate cancer with 89Zr immuno-PETPatient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.Utility of FDG-PET in clinical neuroendocrine prostate cancer.Disparities in castration-resistant prostate cancer trials.Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyPI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Radiation therapy in the treatment of minor salivary gland tumors.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Current and emerging treatment options for nasopharyngeal carcinoma.Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingApplying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for SurveillanceThe relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positThe Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter StudyThe natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery.Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases.Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.Androgen receptor signaling regulates DNA repair in prostate cancers.A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy.Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy.Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study.Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.Travel distance and stereotactic body radiotherapy for localized prostate cancer.ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources.Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases.
P50
Q26863511-1608EB28-0DDB-4BE0-8439-5741CEC1261DQ30643770-F1792432-3DFB-47BF-9EFE-ACEC32357D61Q33793232-B0B48642-00B2-4BBD-A3DF-A3BEDB063969Q33924077-0ADF3967-76F5-4596-AEC7-9B0225582AA2Q34218232-09FE3B2A-F433-4014-99F5-F5B72C3A8412Q35166475-D7F9A6F3-8094-42D6-AB3E-2F75863F0A89Q35215028-8DC2A77B-8398-4337-BAC0-A2ECE87E9D8AQ35231246-BB4AB699-E12E-4490-939C-56A9D5703E3EQ35544056-36222E7B-45CF-428C-8862-E94EB9D8EB94Q35610581-20FF06A8-F227-4DA7-ABF8-3ABBC372BF53Q35841958-ABD4A826-8C76-41CD-9164-5D4A11371982Q35985270-4B2473D0-60F1-418E-80A1-64E36AECEAD3Q36359374-EE73DE44-A2BD-44E6-BB5C-07C119FD6B77Q36491493-C1942394-BE64-4FAA-8134-933D58ECB7EEQ36536355-EFEBE23D-9FD9-4ED0-B3DD-0BE287A66133Q36672787-748EB710-2C29-4D4B-8D8B-7CEF1F53A546Q36952314-FBABE79F-E181-430F-9024-39DDF60AE84BQ37192658-0008B4B3-FD5A-4E25-8C61-4E3935C5E30BQ37193603-698994BF-04D5-43FF-9521-123FF242E935Q37213044-1A934E90-7A21-401E-8AD8-01D5D797EEDBQ37214143-694C8DD1-209D-46EF-977D-E76B5FFBFF20Q38011485-6B3E8BF2-E1C5-4169-91ED-F6B022354E3DQ38530671-F0CE9466-4765-4D0E-884B-721AE265B5E1Q38830640-E905C1F0-56D8-4B2E-8FB1-70DD1178A423Q38990477-E66CFFF9-D97C-4F2D-BB4B-A125F1589092Q39096880-3C952FE5-28C0-43C9-8AB1-67036A5380BBQ39429155-27C1ED6E-AB1C-498B-BD26-EB2BE413C0BFQ39514110-B59BE7D4-697A-41B4-92B2-3785CD2BC4C1Q40171745-DF41B17D-856B-4A7A-94F2-942281EBBEC9Q40839312-55AC9453-D60D-4997-9169-65C40A0AE1F0Q41340312-CBA7854F-1072-462A-ADCE-6F839F5B055BQ41441170-171607C2-E4FD-4F09-8B99-1997B729D237Q41903833-B56C4CAE-BD28-430F-8A08-E736F81F94ECQ42259632-F0198302-5BAC-4F07-A6F3-E3588ECC37E5Q43122705-0DF35F03-D301-4629-A2CD-9A049667686EQ44124651-99D7ED0E-48A7-4C51-92AC-5E3ADB4A8845Q45904187-15A59901-410E-4D38-A1BD-2B5692BF513FQ46084626-BF8FCCBE-1175-4310-9E54-514D7195A1DBQ46456368-6F9A2496-7335-415B-97AF-4E6BDDB42117Q46969346-004EDA28-C710-4540-BF79-DC14705251FD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel E Spratt
@es
Daniel E Spratt
@nl
Daniel E Spratt
@sl
Daniel E. Spratt
@en
type
label
Daniel E Spratt
@es
Daniel E Spratt
@nl
Daniel E Spratt
@sl
Daniel E. Spratt
@en
altLabel
Daniel Spratt
@en
prefLabel
Daniel E Spratt
@es
Daniel E Spratt
@nl
Daniel E Spratt
@sl
Daniel E. Spratt
@en
P106
P1153
36019569900
P21
P31
P496
0000-0002-5973-4741